Determination of Angiotensin-Converting Enzyme Inhibitor, Perindopril Erbumine, in Bulk and Tablet Dosage Form with HPLC

Nagalakshmi, Chatragadda

doi:10.9734/acsj/2012/2045

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Angiotensinconverting enzyme catalyze the conversion of angiotensin I to angiotensin II, which is a potent peripheral vasoconstrictor that stimulate aldosterone secretion by the adrenal cortex and provides a negative feedback on renin secretion (Riyaz et al, 2012;Sridevi et al, 2012;Varma et al, 2013;Prajapati et al, 2011). Inhibition of angiotensinconverting enzyme results in decreased plasma angiotensin II, leading to decreased vasoconstriction, increased plasma renin activity and decreased aldosterone secretion, which results in diuresis and natriuresis and may be associated with a small increase of serum potassium (Ratnaparkhi, 2012;Patil et al, 2013;Nagalakshmi et al, 2012). Perindopril erbumine tablet is indicated for the treatment stable coronary artery disease and hypertension.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of anaphylactic reaction as an adverse event for perindopril erbumine tablets

Krishnan

Krishnasamy

2014

Int Curr Pharm J

View full text Add to dashboard Cite

Perindopril erbumine is a tert-butylamine salt of perindopril used in the treatment of stable coronary artery disease and hypertension. The present study was aimed to evaluate the anaphylactic reaction as an adverse event for perindopril erbumine tablets. Electronic extraction of data from the safety database for this report includes all cases of anaphylactic reaction where perindopril was a primary or co-suspect drug. The study result have shown that there were overall 205 case reports for perindopril in the database, of which 200 cases were assessed as (potentially) perindopril and 05 were assessed as non-perindopril product. From the 200 case reports, 141 were serious and 59 were non-serious. Out of the 141 serious cases, 137 cases were medically confirmed while remaining 04 cases were consumer reports. Of the total 205 case reports there were five cases wherein the patient experienced anaphylactic reaction. The study concludes that three out of five cases entered in the drug safety database suggestive of a possible association between perindopril and anaphylactic reaction.DOI: http://dx.doi.org/10.3329/icpj.v3i4.18265 International Current Pharmaceutical Journal, March 2014, 3(4): 254-258

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of anaphylactic reaction as an adverse event for perindopril erbumine tablets

Krishnan

Krishnasamy

2014

Int Curr Pharm J

View full text Add to dashboard Cite

show abstract

Analytical Techniques for the Estimation of Perindopril Erbumine: A Review

Pathak¹,

Kaushal²,

Patel³

2021

CPA

View full text Add to dashboard Cite

Aims: According to Matthew R Alexander, MD, PhD Fellow, Division of Cardiovascular Medicine, Department of Internal Medicine, Physician Scientist Training Program, Vanderbilt University School of Medicine, have written in a article that an estimated 26% of the world’s population (972 million people) has hypertension, and the prevalence is expected to increase to 29% by 2025, driven largely by increases in economically developing nations. So many new drugs are developed for its treatment. Perindopril erbumine is a one of the ACE inhibitor for treating hypertension and heart failure. Background: Perindopril is officially listed in USP, BP and EP. There are number of methods reported for its estimation. Objective: Objective of this review article is to include various analytical techniques used for its estimation in bulk, dosage form or any bilological fluids. Method: This paper includes various analytical techniques like UV-spectroscopic method, stability indicating liquid chromatography method, Thermo-Radio and Photo stability study, Stability indicating UHPLC-DAD method, LC-MS/MS electro spray ionization validated method, LC-MS/MS bio-analytical method, Thin layer chroamtography and many more. Result: This paper has included all different analytical techniques used for estimation of Perindropril. Conclusion: In this review, we summarized the analytical detection techniques used in identification, quantification of perindopril erbumine as well as its related substances. The Spectroscopy and RP-HPLC methods are widely applied for activity determination of perindopril erbumine as well as its related substances in pharmaceutical dosage forms. This all techniques can be precisely applied on Perindopril erbumine. Other: There is still scope for the development of new selective and specific analytical techniques for quantization of this drug.

show abstract

Direct Spectrophotometric Determination of Perindopril Erbumine and Enalapril Maleate in Pure and Pharmaceutical Dosage Forms using Bromocresol Green

Sakur

Balid

2021

RJPT

View full text Add to dashboard Cite

In this article, it has been reported new, simple, sensitive and direct spectrophotometric methods for the determination of Perindopril Erbumine (PPE) and Enalapril Maleate (ENL) in pure and in pharmaceutical forms. Spectrophotometric methods are based on the formation of yellow colored ion-pair complexes between PPE, ENL and sulphonphthalein acid dye, Bromocresol green (BCG) into chloroform were measured at the wavelength of 414 and 415nm for PPE and ENL, respectively. The optimal analytical conditions were determined. The obtained complexes (BCG: PPE) and (BCG: ENL) reached maximum absorbance directly after formation at room temperature for a stability period of 24 h. Beer’s law were obeyed in the concentration ranges of (2-20)µg/mL for PPE and (8- 44)µg/mL for ENL, the limit of detection of 0.125μg/mL and 0.230μg/mL were found for PPE and ENL, respectively. The molar absorptivity coefficients were 4.4045*104 L.moL-1.cm-1 for PPE and 1,9330*104 L.moL-1.cm-1 for ENL. The stoichiometry of the complexes formed between PPE, ENL and BCG were 1:1. No interference was observed from common excipients occurred in pharmaceutical formulations and the proposed methods have been successfully applied to determine the PPE and ENL in some pharmaceutical products and in ENL combination dosage forms with hydrochlorothiazide (HCTZ). The proposed methods were successfully validated to be utilized in the quantitative analysis of PPE and ENL in their pure and pharmaceutical products. A good agreement between the developed spectrophotometric methods with the results obtained from official reference methods for the determination of the two drugs in some real samples demonstrate that the proposed methods were suitable to quantify PPE and ENL in pharmaceutical formulations.

show abstract

Determination of Angiotensin-Converting Enzyme Inhibitor, Perindopril Erbumine, in Bulk and Tablet Dosage Form with HPLC

Abstract: Aim: To develop and validate a simple HPLC method for the determination of perindopril erbumine (PDE) in bulk and tablets.

Cited by 3 publications

References 23 publications

Evaluation of anaphylactic reaction as an adverse event for perindopril erbumine tablets

Evaluation of anaphylactic reaction as an adverse event for perindopril erbumine tablets

Analytical Techniques for the Estimation of Perindopril Erbumine: A Review

Direct Spectrophotometric Determination of Perindopril Erbumine and Enalapril Maleate in Pure and Pharmaceutical Dosage Forms using Bromocresol Green

Contact Info

Product

Resources

About